MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
Rhea-AI Summary
MannKind (Nasdaq: MNKD) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, with a live webcast and a replay available via the company’s investor relations website.
Positive
- None.
Negative
- None.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 29 | 3Q25 earnings date | Neutral | +0.2% | Third-quarter results and conference call scheduled for November 5, 2025 |
| Jul 30 | 2Q25 earnings date | Neutral | -2.3% | Second-quarter results and conference call scheduled for August 6, 2025 |
| May 01 | 1Q25 earnings date | Neutral | +1.0% | First-quarter results and webcast scheduled for May 8, 2025 |
| Feb 19 | 4Q24 earnings date | Neutral | +2.7% | Fourth-quarter and full-year results scheduled after market close February 26, 2025 |
| Oct 31 | 3Q24 earnings date | Neutral | +1.4% | Third-quarter results and webcast scheduled for November 7, 2024 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Comparable earnings-date announcements produced four positive and one negative 24-hour reactions, with an average move of 0.6%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026.
MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update.
The webcast of the conference call will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in the same location within 24 hours following the call and will be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.

Contacts: Investor Relations Kate Miranda (617) 921-5461 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com